Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 870 across all filing types
Latest filing 2025-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司关于2024年度会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm Zhongshen Zhonghuan CPA Firm for the year 2024. It details the qualifications, audit records, risk capacity, quality management, audit work plan, human resources, information security, and overall evaluation of the audit firm. The content focuses on the audit firm's performance and compliance during the audit process for the company, rather than presenting the company's financial statements or audit results themselves. The document is not a full Annual Report (10-K) or an Interim Report (IR), nor is it a simple announcement or certification. It is a standalone audit-related report evaluating the auditor's performance and compliance, which fits the category of Audit Report / Information (AR). The document length is 2607 characters, which is relatively short but contains substantive audit evaluation content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2024
2025-04-28 Chinese
圣湘生物科技股份有限公司2024年度独立董事述职报告（曹亚）
Management Reports Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" (2024 Annual Independent Director's Work Report) for 圣湘生物科技股份有限公司. It is a detailed report by an independent director describing their duties, attendance at board and committee meetings, oversight activities, and opinions on company governance and financial reporting for the year 2024. The content focuses on the independent director's role, compliance with laws and regulations, internal controls, audit firm engagement, and governance matters. It is not a financial report like an annual or interim report, nor is it an announcement or proxy material. It is a management-related report specifically from an independent director about their work and oversight during the year. This fits best under the category of Management Reports (MDA), which includes detailed explanations of business trends, governance, and oversight activities by management or directors.
2025-04-28 Chinese
圣湘生物科技股份有限公司第二届董事会2025年第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 2025 fifth meeting of the second board of directors of 圣湘生物科技股份有限公司. It includes multiple agenda items such as approval of the 2024 annual board work report, the 2024 annual report and its summary, remuneration plans, independent director independence self-assessment, audit committee reports, internal control evaluation, auditor performance evaluation, ESG report, profit distribution plan, appointment of audit institutions, fundraising usage report, bank credit application, quality improvement action plans, the 2025 first quarter report, authorization for mid-term dividend plans, and the proposal to convene the 2024 annual shareholders meeting. The document repeatedly states that the detailed reports (annual report, ESG report, audit reports, quarterly report, etc.) are published separately on the Shanghai Stock Exchange website and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself is a board meeting resolution announcement summarizing approvals and decisions, not the full reports themselves. It is a formal disclosure of board/management decisions and meeting outcomes, consistent with the category of Board/Management Information (MANG). The document length (5940 characters) and content confirm it is not a full financial report or earnings release but a board meeting resolution announcement.
2025-04-28 Chinese
中审众环会计师事务所（特殊普通合伙）关于圣湘生物科技股份有限公司非经营性资金占用及其他关联资金往来情况汇总的专项审核报告
Regulatory Filings
2025-04-28 Chinese
圣湘生物科技股份有限公司2025年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 First Quarter Report" of 圣湘生物科技股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheet, profit and loss statement, and cash flow statement for the first quarter of 2025. The report is unaudited as indicated. The content includes comprehensive financial data and analysis for a period shorter than a full fiscal year, which matches the definition of an Interim / Quarterly Report (IR). The document length is over 11,000 characters, so it is not a mere announcement or publication notice. Therefore, the document is classified as an Interim / Quarterly Report (IR). Q1 2025
2025-04-28 Chinese
圣湘生物科技股份有限公司关于2024年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report from 圣湘生物科技股份有限公司 regarding the 2024年度募集资金存放与实际使用情况 (2024 annual report on the storage and actual use of raised funds). It includes specifics on the amount of funds raised, usage, balances, management, and compliance with regulatory requirements. It references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, and includes auditor and sponsor verification statements. The document is about the management and use of capital raised by the company, which aligns with a Capital/Financing Update. It is not an announcement of a report but the report itself, with substantive financial data and analysis on fundraising and fund usage. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2025-04-28 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.